top of page

Mass Device Highlights First Independent Head-to-Head TMS Study

Jul 18, 2019

Professor of Psychiatry, Dr. Marcus Heilig, and BrainsWay CEO, Yaacov Michlin, report on the comparatively stronger MDD response and remission rates from the use of BrainsWay Deep TMS in conjunction with medication.

BrainsWay touts results of dTMS study for depression

Recent Posts

See All

Non-Drug, Non-Invasive, FDA-Cleared Device to Treat OCD

We Need a Clearer Understanding of Treatment-Resistant Depression, Experts Say

Transcranial Magnetic Stimulation Shows Promise for Alcohol Addiction

Comments

bottom of page